Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 21, 2023
Event: Entry into a Material Definitive Agreement regarding a Private Placement of common shares.
Key Financial Metrics
This filing reports on a capital raise rather than operational financial performance. Key metrics include:
- Gross Proceeds: Expected $37.5 million.
- Shares Issued: 11,011,406 common shares.
- Purchase Price: $3.40 per share for most investors; $3.91 per share for certain officers and directors.
- Use of Proceeds: Clinical and product development for DM199 (including the pivotal ReMEDy2 trial), working capital, and general corporate purposes.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of Securities Purchase Agreements with accredited investors, including existing stockholders, directors, and officers. The transaction is expected to close on or about June 23, 2023, subject to customary conditions. This represents a significant increase in the company's share count and cash position upon closing.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize the net proceeds to advance the pivotal ReMEDy2 trial for its lead asset, DM199.
Registration Rights: The Company agreed to file a Resale Registration Statement within 10 business days of closing and use commercially reasonable best efforts to have it declared effective within 30 calendar days (or 75 days in the event of a full review).
Risks and Contingencies:
- Liquidated Damages: If the Company fails to meet filing deadlines or keep the Resale Registration Statement effective, it must pay liquidated damages to Purchasers.
- Expenses: The Company is responsible for all fees and expenses related to the Registration Rights Agreement and indemnification of selling holders.
- Placement Agent Fees: The Company engaged Craig-Hallum Capital Group LLC as the placement agent and agreed to pay a fee based on a percentage of gross proceeds from certain investors.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting offering expenses and placement agent fees.
- Confirm the filing and effectiveness date of the Resale Registration Statement to assess potential dilution from secondary sales.
- Review the specific terms of the liquidated damages clause in the Registration Rights Agreement.
- Monitor updates on the ReMEDy2 trial progress as the primary use of funds.